Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.98 USD | +4.86% | +6.36% | -28.31% |
Jun. 01 | Transcript : Immunocore Holdings plc - Special Call | |
May. 29 | Immunocore Converts Skin Cancer Therapy Phase 2/3 Trial to Phase 3 | MT |
Evolution of the average Target Price on Immunocore Holdings plc
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Immunocore Holdings plc
Mizuho Securities | |
Leerink Partners | |
Oppenheimer | |
Cantor Fitzgerald | |
Baird | |
Needham & Co. | |
Capital One Securities | |
Guggenheim | |
Goldman Sachs | |
Jefferies & Co. | |
BTIG | |
Canaccord Genuity | |
Barclays | |
HC Wainwright | |
Morgan Stanley | |
Cowen | |
JPMorgan Chase | |
Ladenburg Thalmann | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- IMCR Stock
- Consensus Immunocore Holdings plc